Confirman dos casos de rápida farmacorresistencia de H1N1

Diariomedico.com
ESPAÑA
MUTACIONES DE LA 'GRIPE A'
Confirman dos casos de rápida farmacorresistencia de H1N1
Un estudio que se publica en Clinical Infectious Diseases confirma que dos pacientes que enfermaron de H1N1 en 2009 desarrollaron cepas farmacorresistentes del virus tras menos de 15 días de tratamiento. Los autores advierten de que el hecho de que terapias cortas puedan llevar a resistencias debe ser tenido en cuenta al atender a los pacientes.

Redacción - Lunes, 29 de Marzo de 2010 - Actualizado a las 12:20h.

Dos pacientes que enfermaron de H1N1 en 2009 desarrollaron cepas farmacorresistentes del virus tras menos de 15 días de tratamiento, según un estudio del National Institute of Allergy and Infectious Diseases de Estados Unidos, parte de los National Institutes of Health (NIH), que se publica en Clinical Infectious Diseases. Los autores advierten de que incluso terapias cortas pueden llevar a resistencias y que los facultativos deben tenerlo en cuenta al plantear el tratamiento.

"El surgimiento de virus de la gripe resistentes no es sorprendente en sí mismo, pero estos casos demuestran que las cepas resistentes pueden surgir tras periodos muy breves de tratamiento farmacológico", afirma Anthony Fauci, director del instituto. "Dado que tenemos un arsenal terapéutico limitado, la situación revela la urgencia de desarrollar nuevos antivirales que ataquen la gripe de forma novedosa".

Ambos pacientes tenían problemas inmunitarios de base debido a enfermedades previas y en los dos casos se recuperaron de la infección.

Matthew Memoli, autor principal del estudio, señala que "aunque el tratamiento recomendado con oseltamivir (comercializado como Tamiflu) es de cinco días, es práctica común que los médicos sigan administrando este fármaco durante más tiempo si el paciente no mejora". Hasta ahora el virus había mutado más frecuentemente a partir de los 24 días de tratamiento con Tamiflu, pero en los individuos estudiados la cepa se volvió resistente en el día 14.

En este caso, uno de los enfermos siguió empeorando. Tras 24 días de terapia con oseltamivir sin cambios, sus médicos le administraron peramivir durante diez días, pero tampoco detuvieron la propagación del virus. Finalmente, la única alternativa que restaba, zanamivir, permitió la recuperación.

Hay que recordar que el H1N1 sólo responde a uno de los dos tipos de fármacos antigripales existentes, los inhibidores de la neuraminidasa, de los que sólo existen tres: oseltamivir (oral), zanamivir (inhalado, comercializado como Relenza) y peramivir (intravenoso y en fase experimental, autorizado por la FDA para ciertos casos).

Precisamente, estos casos son preocupantes, explica Memoli, porque indican que la mutación que provoca resistencia a oseltamivir también reduce la susceptibilidad del virus al peramivir. El problema es que el paciente queda entonces con una única alternativa que, al tomarse por inhalación, no es administrable a individuos en estado muy grave o que requieren de ventilación asistida.

"Como médicos, debemos utilizar sabiamente las opciones terapéuticas que tenemos a nuestra disposición, especialmente en caso de personas con una infección prolongada o cuando un fármaco no obtiene resultados tras su periodo recomendado de administración", concluye Memoli.



Friday, March 26, 2010 Contact:
Anne A. Oplinger, 301-402-1663 / aoplinger@niaid.nih.gov
Rapid Development of Drug-Resistant 2009 H1N1 Influenza Reported in Two Cases
Reevaluation of Treatment Strategies for Prolonged Infection Urged

Two people with compromised immune systems who became ill with 2009 H1N1 influenza developed drug-resistant strains of virus after less than two weeks on therapy, report doctors from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Doctors who treat prolonged influenza infection should be aware that even a short course of antiviral treatment may lead to drug-resistant virus, say the authors, and clinicians should consider this possibility as they develop initial treatment strategies for their patients who have impaired immune function.

Both patients described in the new report developed resistance to the key influenza drug oseltamivir (Tamiflu), and one also demonstrated clinical resistance to another antiviral agent, now in experimental testing, intravenous peramivir, note senior authors Matthew J. Memoli, M.D., and Jeffery K. Taubenberger, M.D., Ph.D. This is the first reported case of clinically significant peramivir-resistant 2009 H1N1 illness, say the scientists. The report is scheduled to appear in print on May 1 in Clinical Infectious Diseases and is now online.

The people in the current case report had immune limitations due to blood stem cell transplants that occurred several years previously. Both recovered from their influenza infections.

"While the emergence of drug-resistant influenza virus is not in itself surprising, these cases demonstrate that resistant strains can emerge after only a brief period of drug therapy," says NIAID Director Anthony S. Fauci, M.D. "We have a limited number of drugs available for treating influenza and these findings provide additional urgency to efforts to develop antivirals that attack influenza virus in novel ways."

The 2009 H1N1 influenza virus is susceptible to just one of the two available classes of anti-influenza drugs, the neuraminidase inhibitors. Besides oseltamivir, other neuraminidase inhibitors are zanamivir (Relenza), which is inhaled, and the intravenously administered investigational drug peramivir. As the H1N1 influenza pandemic unfolded, laboratory tests of virus strains isolated from patients showed that some strains contained a genetic mutation (the H275Y mutation) that makes the virus less susceptible to some neuraminidase inhibitors.

The two people in the current case study had pre-existing medical conditions that impaired their immune system function before contracting 2009 H1N1 flu. Strains of 2009 H1N1 influenza containing the H275Y mutation had been reported previously in people with diminished immune function, but in previous cases the mutation arose after more than 24 days of continuous therapy. In the newly described cases, the mutation appeared after 14 days in one individual and after nine days in the second.

"Although the recommended length of treatment with oseltamivir is five days, it is common for physicians to continue giving this first-line drug longer if the patient does not improve," says Dr. Memoli.

Both people in the current report received oseltamivir for extended periods but they continued to shed virus in their nasal secretions throughout treatment. When one patient’s condition worsened despite 24 days of oseltamivir treatment, doctors administered peramivir for 10 days. The drug did not reduce viral shedding and the patient remained ill, demonstrating what the authors described as clinically significant resistance to peramivir. Next, doctors administered the only other available flu drug, zanamivir, for 10 days. The person then fully recovered.

"Additional, larger studies are needed to further refine our findings,” says Dr. Memoli. “But these cases of rapid appearance of drug-resistant 2009 H1N1 influenza in immune-compromised patients are worrisome and should prompt clinicians to reconsider how they use available flu drugs."

The mutation that allows 2009 H1N1 to resist oseltamivir also significantly reduces the virus's susceptibility to peramivir. If a relatively short course of oseltamivir causes a mutant flu strain to emerge in a particular patient, that person may not respond to peramivir. Zanamivir might be a good choice if a patient does not respond within a few days to oseltamivir, Dr. Memoli says. However, because zanamivir must be inhaled, patients who are very ill and whose breathing is mechanically supported cannot be given zanamivir.

"As clinicians, we should carefully consider our treatment options and use all the drugs available to us wisely. This is especially important in a patient with prolonged infection or when an antiviral drug fails to cure the patient after the recommended course of treatment," says Dr. Memoli.

NIAID scientist Rachel J. Hrabal contributed to this study along with Arash Hassantoufighi and Maryna C. Eichelberger, Ph.D., of the FDA.

Visit www.flu.gov for one-stop access to U.S. government information on influenza. Also, visit NIAID's flu Web portal at http://www3.niaid.nih.gov/topics/Flu/.
NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

The National Institutes of Health (NIH) — The Nation's Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
http://www.nih.gov/news/health/mar2010/niaid-26.htm

----------
Reference:
MJ Memoli et al. Rapid selection of oseltamivir and peramivir resistant pandemic H1N1 during therapy in two immunocompromised hosts. Clinical Infectious Diseases DOI: 10.1086/651605. (online March 26, 2010)